Telomir Pharmaceuticals, Inc.: Form 10-Q for the period ended Jun 30, 2025
Filed with the SEC on Aug 14, 2025 and accepted by EDGAR at Aug 14, 2025, 16:02 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2025-04-01 to 2025-06-30 | $42.8k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2025-01-01 to 2025-06-30 | $379.8k | us-gaap:ResearchAndDevelopmentExpense |
| Interest expense | 3 months2025-04-01 to 2025-06-30 | $1.3k | us-gaap:InterestExpenseNonoperating |
| Interest expense | 6 months2025-01-01 to 2025-06-30 | $1.4k | us-gaap:InterestExpenseNonoperating |
| Net income | 3 months2025-04-01 to 2025-06-30 | −$5.1m | us-gaap:NetIncomeLoss |
| Net income | 6 months2025-01-01 to 2025-06-30 | −$7.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2025-04-01 to 2025-06-30 | $0.17 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2025-01-01 to 2025-06-30 | $0.24 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2025-04-01 to 2025-06-30 | $0.17 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2025-04-01 to 2025-06-30 | 30,010,165 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2025-01-01 to 2025-06-30 | 30,265,285 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2025-01-01 to 2025-06-30 | −$1.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2025-06-30 | $754.3k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-06-30 | $829.6k | us-gaap:AssetsCurrent |
| Total assets | At period end2025-06-30 | $829.6k | us-gaap:Assets |
| Current liabilities | At period end2025-06-30 | $348.4k | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-06-30 | $348.4k | us-gaap:Liabilities |
| Shareholders' equity | At period end2025-06-30 | $481.2k | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001641172-25-023970. Last ingested by Listed: Oct 27, 2026, 16:31 ET. Listed shows no prices and gives no investment advice.